Table 1 BI 894999 effect on cell proliferation (alamarBlue® assay) for hematological cell lines
Indication | Cell line | EC50 (nM) | Mutation/Karyotype/Subtype | Experiments (n) |
|---|---|---|---|---|
AML | HL-60 | 2.7 ± 0.1 | MYC amplification | 2 |
AML | Kasumi-1 | 2.8 ± 0.4 | AML1-ETO | 2 |
AML | Kasumi-3 | 3.4 ± 1.5 | EVI1 overexpression | 3 |
AML | KG-1 | 6.2 ± 2.2 | NRAS | 2 |
AML | MOLM-13 | 12.8 ± 3.4 | MLL-AF9; FLT3-ITD | 3 |
AML | MOLM-13 GFP | 14.3 | MLL-AF9; FLT3-ITD | 1 |
AML | MUTZ-3 | 12.8 ± 11.2 | EVI1 rearrangement | 3 |
AML | MV-4-11B | 6.8 ± 4.0 | MLL-AF4; FLT3-ITD | 9 |
AML | MV-4-11B GFP | 2.9 ± 0.9 | MLL-AF4; FLT3-ITD | 4 |
AML | NOMO-1 | 5.7 ± 4.1 | MLL-AF9 | 2 |
AML | OCI-AML3 | 2.3 ± 0.5 | NPM1 gene mutation (type A) and DNMT3A R882C mutation | 2 |
AML | SKM-1 | 10.2 ± 1.5 | EZH2-Y641C | 2 |
AML | THP-1 | 6.3 ± 2.9 | MLL-AF9 | 3 |
AML | THP-1 GFP | 4.1 ± 2.0 | MLL-AF9 | 2 |
CML | K562 | >10,000 | 2 | |
CML | MOLM-1 | 53.4 ± 34.8 | EVI1 overexpression | 3 |
T-ALL | CCRF-CEM | 175 ± 58 | 2 | |
T-ALL | J.RT3-T3.5 | 11 ± 4 | 2 | |
T-ALL | MOLT-3 | 14.4 ± 6.5 | 2 | |
T-ALL | MOLT-4 | 40.7 ± 28.7 | 2 | |
MM | AMO-1 | 28 ± 15 | Plasmacytoma | 3 |
MM | L-363 | 13.7 ± 6.2 | t(11;14) | 2 |
MM | MM.1R | 2.5 ± 2.1 | t(14;16) | 2 |
MM | MOLP-8 | 5.3 ± 2.8 | t(11;14) | 9 |
MM | MOLP-8 GFP | 21.5 ± 10.8 | t(11;14) | 4 |
MM | NCI-H929 | 3.6 ± 2.0 | t(4;14) | 2 |
MM | OPM-2 | 8.9 ± 4.7 | t(4;14) | 2 |
MM | OPM-2 GFP | 12 | t(4;14) | 1 |
MM | RPMI 8226 | 25 ± 9 | t(14;16) | 3 |
MM | U266 B1 | 14.3 ± 7.4 | 6 | |
Lymphoma | HBL-1 | 7.1 ± 5.2 | DLBCL, ABC type | 2 |
Lymphoma | OCI-Ly18 | 5.6 ± 0.9 | DLBCL, ABC type | 2 |
Lymphoma | OCI-Ly3 | 8.2 ± 2.3 | DLBCL, ABC type | 2 |
Lymphoma | Pfeiffer | 10.7 ± 2.7 | DLBCL, ABC type | 2 |
Lymphoma | RI-1 | 6.2 ± 1.9 | DLBCL, ABC type | 2 |
Lymphoma | SU-DHL2 | 10.7 ± 3.2 | DLBCL, ABC type | 2 |
Lymphoma | TMD8 | 9.7 ± 3.7 | DLBCL, ABC type | 13 |
Lymphoma | Toledo | 6.0 ± 1.1 | DLBCL, ABC type | 3 |
Lymphoma | U-2932 | 4.3 ± 2.1 | DLBCL, ABC type | 3 |
Lymphoma | DB | 11.6 ± 7.6 | DLBCL, GCB type | 2 |
Lymphoma | DOHH-2 | 6.2 ± 0.8 | DLBCL, GCB type | 2 |
Lymphoma | HT | 11.6 ± 8.1 | DLBCL, GCB type | 2 |
Lymphoma | OCI-Ly7 | 14.2 ± 6.4 | DLBCL, GCB type | 2 |
Lymphoma | OCI-Ly19 | 13.2 ± 4.3 | DLBCL, GCB type | 4 |
Lymphoma | RC-K8 | 7.8 ± 0.9 | DLBCL, GCB type | 2 |
Lymphoma | RL | 18.2 ± 10.0 | DLBCL, GCB type | 2 |
Lymphoma | SU-DHL4 | 13.3 ± 4.5 | DLBCL, GCB type | 3 |
Lymphoma | SU-DHL6 | 13.4 ± 1.2 | DLBCL, GCB type | 2 |
Lymphoma | MHH-PREB-1 | 24.4 ± 1.2 | B cell lymphoma | 2 |
Lymphoma | JEKO-1 | 7.9 ± 2.1 | Mantle cell lymphoma | 2 |
Lymphoma | DERL-2 | 10.6 ± 9.5 | T cell lymphoma | 2 |
Lymphoma | HuT78 | 7.1 ± 3.7 | T cell lymphoma | 3 |
Lymphoma | SR-786 | 77.3 ± 17.3 | Anaplastic large-cell lymphoma | 2 |
